Weekly versus three weeks chemotherapy for advanced ovarian cancer: a meta-analysis.

Oncotarget

PubMedID: 27509061

Marchetti C, De Felice F, Musella A, Palaia I, Monti M, Musio D, Muzii L, Tombolini V, Panici PB. Weekly versus three weeks chemotherapy for advanced ovarian cancer: a meta-analysis. Oncotarget. 2016;.
AIM
Three weeks paclitaxel and carboplatin has been considered the standard of care for primary treatment of ovarian cancer (OC). Whether weekly therapy will further improve the clinical outcomes or not is still unclear. We conducted a meta-analysis to compare the two regimens.

METHOD
Articles were selected with a systematic approach, using PubMed databases. Trials concerning comparison between carboplatin plus weekly paclitaxel (dose-dense regimen) and carboplatin plus paclitaxel every 3 weeks were considered. Outcomes included overall survival (OS), progression free survival (PFS) and severe acute toxicity.

RESULTS
Dose-dense regimen was associated with significant improvement of PFS compared with standard schedule, with HR of 0.73 (95% CI 0.61-0.88, p = 0.001). There was no difference in OS between treatment regimens (HR 0.95, 95% CI 0.77-1.16, p=0.06), as well as in term of severe acute toxicity.

CONCLUSION
Dose-dense regimen is superior to standard schedule in terms of PFS. Further studies are necessary to firmly confirm this evidence in advanced OC treatment.